122 related articles for article (PubMed ID: 2471012)
1. Serum lipids, lipoproteins, hemodynamics, and hemostasis in doxazosin-treated monkeys.
Karge WH; Kowala MC; Weiner EJ; Nicolosi RJ
J Cardiovasc Pharmacol; 1989; 13 Suppl 2():S25-9; discussion S29-30. PubMed ID: 2471012
[TBL] [Abstract][Full Text] [Related]
2. Effects of prazosin on hemodynamics, hemostasis, and serum lipid and lipoprotein levels in normal and hypercholesterolemic monkeys.
Karge WH; Weiner EJ; Kowala MC; Graham RM; Nicolosi RJ
Am J Med; 1989 Jan; 86(1B):19-23. PubMed ID: 2913768
[TBL] [Abstract][Full Text] [Related]
3. Effects of doxazosin, an alpha 1-adrenergic inhibitor, on plasma lipid and lipoprotein levels, low density lipoprotein metabolism and cholesterol absorption in cynomolgus monkeys.
Stucchi AF; Vespa DB; Terpstra AH; Nicolosi RJ
Atherosclerosis; 1993 Nov; 103(2):255-66. PubMed ID: 8292100
[TBL] [Abstract][Full Text] [Related]
4. The effects of doxazosin on platelet aggregation, platelet adhesion and blood coagulation in cynomolgus monkeys.
Weiner EJ; Stucchi AF; Foxall TL; Shwaery GT; Yoganathan S; Nicolosi RJ
Atherosclerosis; 1994 May; 107(1):35-44. PubMed ID: 7945557
[TBL] [Abstract][Full Text] [Related]
5. Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension.
Pool JL; Taylor AA; Nelson EB
Am J Med; 1989 Aug; 87(2A):57S-61S. PubMed ID: 2569825
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of hepatic cholesterol synthesis by the alpha 1-adrenoceptor blocker doxazosin in the hypercholesterolemic golden hamster.
Jansen H; Lammers R; Baggen MG; Penders JM; Birkenhäger JC
Life Sci; 1989; 44(15):1013-7. PubMed ID: 2564614
[TBL] [Abstract][Full Text] [Related]
7. Effect of doxazosin on plasma lipids and atherogenesis: a preliminary report.
Kowala MC; Nicolosi RJ
J Cardiovasc Pharmacol; 1989; 13 Suppl 2():S45-9; discussion S49. PubMed ID: 2471015
[TBL] [Abstract][Full Text] [Related]
8. Dose-related effects of doxazosin on plasma lipids and aortic fatty streak formation in the hypercholesterolemic hamster model.
Foxall TL; Shwaery GT; Stucchi AF; Nicolosi RJ; Wong SS
Am J Pathol; 1992 Jun; 140(6):1357-63. PubMed ID: 1351367
[TBL] [Abstract][Full Text] [Related]
9. Doxazosin and cholestyramine similarly decrease fatty streak formation in the aortic arch of hyperlipidemic hamsters.
Kowala MC; Nunnari JJ; Durham SK; Nicolosi RJ
Atherosclerosis; 1991 Nov; 91(1-2):35-49. PubMed ID: 1687433
[TBL] [Abstract][Full Text] [Related]
10. Influence of doxazosin on lipid transport in rats and hamsters.
Ontko JA; Woodside WF
J Cardiovasc Pharmacol; 1989; 13 Suppl 2():S31-6; discussions 36-7. PubMed ID: 2471013
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of doxazosin and atenolol on serum lipids and blood pressure in hypertensive smokers.
Talseth T; Westlie L; Daae LN
J Hypertens Suppl; 1990 Sep; 8(5):S47-51. PubMed ID: 1981077
[TBL] [Abstract][Full Text] [Related]
12. Selective alpha 1 inhibition with doxazosin in hypertensive smokers and non-smokers: haemodynamic and metabolic effects.
Westheim A; Daae LN; Kierulf P; Brusletto B; Holme I; Syvertsen JO
J Hypertens Suppl; 1990 Sep; 8(5):S41-6. PubMed ID: 1981076
[TBL] [Abstract][Full Text] [Related]
13. Studies of serum lipids in hypercholesterolaemic rabbits treated with doxazosin.
Leren TP; Berg K
Scand J Clin Lab Invest; 1988 Jun; 48(4):313-7. PubMed ID: 2907180
[TBL] [Abstract][Full Text] [Related]
14. Effects of doxazosin on diet-induced hypercholesterolemia in C57BR/cdJ mice.
Swindell AC; Valentine JJ
Am J Cardiol; 1987 May; 59(14):29G-34G. PubMed ID: 2884850
[TBL] [Abstract][Full Text] [Related]
15. Effects of doxazosin and other antihypertensives on serum lipid levels and lipoprotein lipase in the C57BR/cdJ mouse.
Krupp MN; Hoover KW; Valentine JJ
J Cardiovasc Pharmacol; 1989; 13 Suppl 2():S11-8; discussion S18-9. PubMed ID: 2471010
[TBL] [Abstract][Full Text] [Related]
16. Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension.
Pool JL
Am J Cardiol; 1987 May; 59(14):46G-50G. PubMed ID: 2884853
[TBL] [Abstract][Full Text] [Related]
17. Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins.
Lehtonen A; Himanen P; Saraste M; Niittymäki K; Marniemi J
Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):77S-81S. PubMed ID: 2939871
[TBL] [Abstract][Full Text] [Related]
18. Effects of adrenoreceptor antagonists and agonists on clearance of emulsion models of triacylglycerol-rich lipoproteins from plasma in rats.
Mackintosh VS; Elsegood CL; Redgrave TG
Clin Exp Pharmacol Physiol; 1991 Nov; 18(11):775-88. PubMed ID: 1685947
[TBL] [Abstract][Full Text] [Related]
19. Doxazosin: a new alpha 1-adrenergic antagonist.
Babamoto KS; Hirokawa WT
Clin Pharm; 1992 May; 11(5):415-27. PubMed ID: 1349855
[TBL] [Abstract][Full Text] [Related]
20. Effects of doxazosin on lipids, lipoprotein lipases, and cholesterol synthesis in the golden hamster.
Jansen H; Lammers R; Baggen MG; Birkenhäger JC
J Cardiovasc Pharmacol; 1989; 13 Suppl 2():S5-9; discussion S9-10. PubMed ID: 2471016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
